LON:RENE ReNeuron Group (RENE) Share Price, News & Analysis GBX 3.38 -0.08 (-2.17%) (As of 02/5/2024) Add Compare Share Share Stock Analysis Stock AnalysisInsider Trades About ReNeuron Group Stock (LON:RENE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ReNeuron Group alerts:Sign Up Key Stats Today's Range 3.28▼ 3.5050-Day Range 3.38▼ 3.3852-Week Range 3.28▼ 11.50Volume177,373 shsAverage Volume578,249 shsMarket Capitalization£1.93 millionP/E RatioN/ADividend Yield0.76%Price TargetN/AConsensus RatingN/A Company OverviewReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.Read More… What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. Receive RENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter. Email Address RENE Stock News HeadlinesReNeuron Group (LON:RENE) Stock Passes Below 200 Day Moving Average - What's Next?November 21 at 4:25 AM | americanbankingnews.comTRADING UPDATES: PetroTal buys Peru's Block 131 for USD5.0 millionMay 17, 2024 | lse.co.ukCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD! November 22, 2024 | Desko Digital (Ad)ReNeuron CFO steps down to pursue other opportunitiesApril 17, 2024 | lse.co.ukMedtech firm IQ Endoscopes plans to create 100 new jobs and raise millionsApril 2, 2024 | msn.comUpland Resources shares soar as company prepares for Sarawak drillingMarch 28, 2024 | lse.co.ukCompany given millions of public money in Welsh Gov's disastrous foray into biotech investments collapses into administrationMarch 22, 2024 | msn.comTRADING UPDATES: ReNeuron appoints administrators as rescue talks failMarch 20, 2024 | lse.co.ukSee More Headlines RENE Stock Analysis - Frequently Asked Questions How have RENE shares performed this year? ReNeuron Group's stock was trading at GBX 3.50 at the start of the year. Since then, RENE stock has decreased by 3.6% and is now trading at GBX 3.38. View the best growth stocks for 2024 here. How were ReNeuron Group's earnings last quarter? ReNeuron Group plc (LON:RENE) issued its quarterly earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share for the quarter, topping the consensus estimate of ($50.20) by $14.30. How do I buy shares of ReNeuron Group? Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR) and Sirius Minerals (SXX). Company Calendar Last Earnings7/20/2020Today11/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryTrading Current SymbolLON:RENE CUSIPN/A CIKN/A Webwww.reneuron.com Phone+44-20-38198400FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.09) Trailing P/E RatioN/A Forward P/E Ratio0.47 P/E GrowthN/ANet Income£-5,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-106.77% Return on Assets-37.91% Debt Debt-to-Equity Ratio14.25 Current Ratio1.51 Quick Ratio2.02 Sales & Book Value Annual Sales£783,000.00 Price / Sales2.46 Cash FlowGBX 5.55 per share Price / Cash Flow0.61 Book ValueGBX 4 per share Price / Book0.84Miscellaneous Outstanding Shares57,170,000Free FloatN/AMarket Cap£1.93 million OptionableNot Optionable Beta0.83 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (LON:RENE) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReNeuron Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ReNeuron Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.